5:57 PM
 | 
Sep 20, 2013
 |  BC Extra  |  Company News

CHMP backs Invokana, Xofigo, Abilify Maintena

EMA's CHMP recommended approval of a number of products, including Invokana canagliflozin from Johnson & Johnson (NYSE:JNJ) to treat Type II diabetes as monotherapy or as add-on therapy in adults. FDA approved the sodium-glucose cotransporter 2 (SGLT2) inhibitor to treat Type II...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >